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Background: LATS1 is a tumor suppressor genes implicated in the pathogenesis of certain types of tumors, but its
role is not known in human glioma.
Methods: Using real-time PCR and immunohistochemistry, we detected the mRNA and protein expression of
LATS1 in glioma. The effect of LATS1 on cell growth and invasion were investigated.
Results: We found that mRNA and protein of LATS1 expression is significantly downregulated in glioma compared
with normal control brain tissues. Furthermore, reduced LATS1 expression was markedly negatively correlated with
WHO grade and KPS (p<0.001 and p<0.001) in glioma patients. Patients with lower LATS1 expression had a
significantly shorter overall survival time than did patients with higher LATS1 expression. Multivariate analysis
suggested that the level of LATS1 expression was an independent prognostic indicator (p<0.001) for the survival of
patients with glioma. Forced expression of LATS1 in glioma U251 cells not only significantly suppressed cell growth,
migration and invasion, but retarded cell cycle progression from G2/M to G1 in vitro. Finally, we found that
overexpressed LATS1 markedly inhibited the expression level of cell cycle factor CCNA1.
Conclusion: These results indicate that LATS1 is an important candidate tumor suppressor and its downregulated
expression may contribute to glioma progression.
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Gliomas are neuroectodermal tumors contributing to
30–45% of all human intracranial tumors that commonly
arise in the white matter of cerebral hemisphere [1]. Due
to its highly invasive ability, angiogenesis and the pres-
ence of necrosis surrounding brain [2,3], malignant gli-
omas are often incurable by surgery alone. The
molecular pathogenesis of malignant gliomas is still un-
clear, thus a major research effort has been directed at
identifying novel specific glioma-associated genes which
might play significant roles in glioma carcinogenesis.
The LATS1 gene, a mammalian homolog of fly LATS
originally isolated in Drosophila as a cell proliferation in-
hibitor [4,5], is a speculative serine/threonine kinase that
localizes to the mitotic apparatus. In mammalian cells,
LATS1 is phosphorylated in a cell-cycle-dependent* Correspondence: bianxiuwu@163.com
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reproduction in any medium, provided the ormanner and complexes with CDC2 in early mitosis. The
N-terminal region of the LATS1 protein binds CDC2 to
form a complex showing decreased H1 histone kinase
activity, indicating a role as a negative regulator of
CDC2/cyclin A [6]. Lats1- knockout mice spontaneously
developed large soft tissue sarcomas and ovarian stromal
cell tumors and a high sensitivity to carcinogenic treat-
ments, suggesting that Lats1 is a tumor suppressor at
least in mice [7]. The human LATS1 gene has been
mapped to chromosome 6q24-25 where loss of heterozy-
gosity has been observed in ovarian [8], cervical [9], and
breast cancers [10]. Overexpressed LATS1 not only
causes G2-M arrest through the inhibition of CDC2 kin-
ase activity in breast cancer cell line in vitro [11], but
also significantly inhibited the tumorigenicity in vivo by
inducing apoptosis [12]. Furthermore, recent investiga-
tions demonstrated that hypermethylation of LATS1
gene promoter which caused downregulated expression
of LATS1 is frequently observed in a few human tumors,
such as breast cancer and astrocytoma [13,14].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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promoter is hypermethylated in the glioma U251 cell
line [13], we hypothesized that expression of LATS1
gene is decreased in glioma pathogenesis. In the present
study, we examined the expression of LATS1 in gliomas
and explored its role as a tumor-suppressor gene in gli-
oma cells in vitro. We provided a preliminary molecular
mechanism of LATS1-mediated cell growth suppression
in glioma.
Materials and methods
Cell culture
Human glioma cells U251 were cultured in RPMI1640
medium (HyClone Inc, USA) supplemented with 12%
new calf bovine serum (NCBS) (PAA Laboratories, Inc,
Austria) in a 37°C, 5% CO2 incubator.
Clinical sample collection
Samples with confirmed pathological diagnosis were col-
lected from Chenggong Hospital, Xiamen University,
China, at the time of first resections before any therapy
with informed consent of all patients and approval of
the ethics committee for the use of these clinical materi-
als for research purposes. This included 17 fresh paired
gliomas and adjacent normal brain tissues, 32 archived
paraffin-embedded normal brain tissues and 103
archived paraffin-embedded gliomas. For the use of
these clinical materials for research purposes, prior writ-
ten consents from the patients and approval from the
Ethics Committees of our hospitals were obtained. All
archived paraffin-embedded glioma samples were staged
according to the 2000 glioma staging system of WHO.
Immunohistochemistry
Paraffin sections (3 μm) from 103 gliomas were deparaf-
finized in 100% xylene and re-hydrated in descending
dilutions of ethanol and water washes. Heat-induced
antigen retrieval was performed followed by blocking en-
dogenous peroxidase activity and non-specific antigen
with peroxidase blocking reagent containing 3% hydro-
gen peroxide and serum, respectively. Subsequently sam-
ples were incubated with goat anti-human LATS1
antibody (1:100) (Abcam, MA, USA) overnight. The sec-
tions were incubated with biotin-labeled rabbit anti-goat
antibody, and subsequently incubated with streptavidin-
conjugated horseradish peroxidase (HRP) (Maixin Inc,
China). Sections were visualized with DAB and counter-
stained with hematoxylin, mounted in neutral gum, and
analyzed using a bright field microscope.
Evaluation of staining
The immunohistochemically stained tissue sections were
reviewed and scored separately by two pathologists
blinded to the clinical parameters. The staining intensitywas scored as previously described [15]. For statistical
analysis, a final staining scores of f 0–1, 2–3, 4–5, and
6–7 were respectively considered to be Negative, weak,
positive and strong expression.
Quantitative real-time PCR (qPCR)
The expression of LATS1 mRNA was measured by
qPCR using SYBR Premix Ex Taq (Takara, Japan) with
an Mx3000P real-time PCR system (Stratagene, La Jolla,
CA, USA). For LATS1 analysis, the sequence for sense
primer was 5’- GTTAAGGGGAGAGCCAGGTCCTT-3’,
and antisense primer was 5’- TCAAGGAAGTCCCCAG-
GACTGT-3’. Parallel reactions were performed using
primers (the sense primer 5’- TCATGGGTGTGAAC-
CATGAGAA -3’ and antisense primer 5’- GGCATG-
GACTGTGGTCATGAG -3’) for GAPDH as an internal
control. Comparative quantification was determined
using the 2-ΔΔCt method [16].
Establishment of glioma U251 cell line stably expressing
LATS1
A LATS1 cDNA clone was purchased from GeneCopoeia
Incorporation. The preparation of pCDF-GFP lentiviral
vectors (SBI Corporation,USA) expressing human LATS1
was performed using the following method: 1) LATS1
open reading frame(ORF) was amplified using the forward
primer 5’- CTACAGATCTATGAAGAGGAGTGAAAAGC-
CAGA-3’ and the reverse primer 5’-CAGTAGATCTT-
TAAACATATACTAGATCGCGATTT -3’ and a BglII
restriction endonuclease site was introduced; 2) LATS1
ORF digested with BglII was cloned into a BglII-digested
pCDF-GFP lentivirus expression vector; 3) The LATS1
sequence was confirmed by sequence analysis. Further,
the resulting lentivirus vector together with two pack-
aging plasmids including pFIV-34 N and pVSV-G were
cotransfected into 293FT cells using lipofectamine 2000
(Invitrogen, Carlsbad, CA). An “empty” vector pCDF-
GFP was utilized as a negative control. After the titers
were determined, the lentiviral particles were used to
infect LAST-negative U251 glioma cells. Colonies with
GFP expression were selected to expand culture and
total RNA of all single cell clones were isolated and
quantitative real-time PCR was performed to detect
the mRNA level of LATS1. Each sample was measured
at least three times.
Western blot analysis
Approximately 5 × 106 U251 cells were lysed in RIPA
Buffer and total protein concentration determined with
BCA assay (Beyotime Inc, China) and 30 μg of total pro-
tein was loaded onto a 8% SDS-PAGE gel. Antibodies
used for Western blot analysis included: CCNA1
(Abcam, MA, USA, 1:500), anti-ACTB antibody (Santa
Cruz, USA, 1:400), and HRP-conjugated anti-rabbit
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periment was performed in triplicate.
Cell proliferation analysis
Cell growth was determined by MTT assay (Sigma,
USA). Briefly, 1 × 103 cells were seeded into 96-well plate
with quadruplicate for each condition. MTT reagent was
added to each well at 5 mg/mL in 20 μL 72 h later and
incubated for another 4 h. The formazan crystals formed
by viable cells were then solubilized in DMSO and mea-
sured at 490 nm for the absorbance (A) values. Each ex-
periment was performed in triplicate.
Plate colony formation assay
Approximately 100 cells were added to each well of a
six-well culture plate. After incubation at 37 °C for
15 days, cells were washed twice with PBS and stained
with Giemsa solution. The number of colonies contain-
ing ≥ 50 cells was counted under a microscope [plate
clone formation efficiency = (number of colonies / num-
ber of cells inoculated) × 100%]. Each experiment was
performed in triplicate.
Cell cycle analysis
The cells grown in the regular growth or the serum-free
media for 36 h were collected, fixed in methanol and
stained with PBS containing 10 μg/mL propidium iodide
and 0.5 mg/mL RNase A for 15 min at 37 °C. The DNA
content of labeled cells was acquired using FACS Caliber
cytometry (BD Biosciences). Each experiment was per-
formed in triplicate.
Migration and invasion assay
Cells growing in the log phase were treated with trypsin
and re-suspended as single-cell solution. A total of
1 × 105 cells were seeded on a fibronectin-coated poly-
carbonate membrane insert in a transwell apparatus
(Corning Inc., Corning, NY). In the lower chamber,
600 μl of RPMI 1640 with 10% NBCS was added as
chemoattractant. After the cells were incubated for 18 h,
the insert was washed with PBS, and cells on the top
surface of the insert were removed by a cotton swab.
Cells adhering to the lower surface were fixed with
methanol, stained with Giemsa and counted under a
microscope in five predetermined fields (×100). All
assays were independently repeated at least three times.
For the matrigel invasion assay, the procedure was simi-
lar to the cell migration assay, except transwell mem-
branes were precoated with 25 μg/μl Matrigel (R&D
Systems, USA). The cells were incubated for 18 hours at
37 °C and 5% CO2 incubator. Cells adhering to the lower
surface were fixed by methanol, stained by Giemsa and
counted under a microscope in five predetermined fields(×200). All assays were independently repeated at least
three times.
Statistical analyses
All statistical analyses were performed using SPSS 13.0
software. The χ2 test was used to analyze the correlation
between the levels of LATS1 expression and clinico-
pathologic characteristics. Survival curves were plotted
using the Kaplan-Meier method and compared using the
log-rank test. The significances of various variables in
survival were analyzed using Multivariate Cox Propor-
tional Hazards Model. One-way ANOVA was used to
determine the differences between groups for all in vitro
analyses. A P value of less than 0.05 was considered sta-
tistically significant.
Results
Downregulated mRNA expression of LATS1 in Glioma
In order to assess the role of LATS1 in glioma, we per-
formed real-time PCR to measure the expression of
LATS1 mRNA transcripts in 17 paired gliomas and their
adjacent brain tissues. As shown in Figure 1A, 13 glioma
tissues showed the markedly decreased expression (>2-
fold change) of LATS1 compared to their matched nor-
mal tissues (Figure 1A).
Reduced LATS1 protein expression in glioma
We measured the expression levels and subcellular
localization of LATS1 protein in archived paraffin-
embedded normal brain and glioma samples using
immunohistochemical staining (Figure 1B1-B5). LATS1
protein is primarily localized within the cytoplasm. Fur-
thermore, we observed expression of LATS1 was mark-
edly decreased in glioma samples compared to normal
brain tissues (p<0.001) (Table 1).
Relationship between clinicopathologic features and
LATS1 expression in glioma patients
The relationships between clinicopathologic features
and LATS1 expression levels in individuals with glioma
were analyzed. We did not find a significant association
of LATS1 expression levels with patient’s age and sex in
103 glioma cases. However, we observed that the expres-
sion level of LATS1 was negatively correlated with
WHO grade (P<0.016) and KPS in glioma patients
(Table 2).
Survival analysis
To investigate the prognostic value of LATS1 expression
for glioma, we assessed the association between levels of
LATS1 expression and patients’ survival using Kaplan–
Meier analysis with the log-rank test. In 103 glioma cases
with prognosis information, we observed that the level
of LATS1 protein expression was significantly correlated
Figure 1 The reduced expression levels of LATS1 mRNA and protein in glioma and Kaplan–Meier plots of overall survival duration in
patients with glioma. A. LATS1 mRNA level was markedly downregulated in glioma samples compared to their matched normal brain tissues. B.
Reduced protein expression of LATS1 in glioma. 1: Strong expression of LATS1 in normal brain; 2: Strong expression of LATS1 in glioma WHO
grade-1; 3: Strong expression of LATS1 in glioma WHO grade-2; 4: Weak expression of LATS1 in glioma WHO grade-3. 5. Negative expression of
LATS1 in glioma WHO grade-4; C. Kaplan–Meier survival analysis of overall survival duration in 103 glioma patients according to LATS1 protein
expression. The log-rank test was used to calculate p values.
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Table 1 The expression of LATS1 protein in Glioma and normal brain
Group Expression Level of LATS1 Protein(n) P
Cases (n) Negative Weak Positive Strong
Glioma 103 23 52 20 8
Normal brain 32 1 3 12 16 P<0.001
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Patients with negative and weak level of LATS1 expres-
sion had poorer survival than those with positive and
strong level of LATS1 expression (P<0.001). In addition,
WHO grade and KPS were also significantly correlated
with patients’ survival (P<0.001 and P<0.001 respect-
ively). To determine whether LATS1 expression is an in-
dependent prognostic factor for glioma, we performed
multivariate analysis of the levels of LATS1 protein ex-
pression adjusted for LATS1 expression, WHO grade,
and KPS of glioma patients. The results showed that the
level of LATS1 expression was an independent prognos-
tic factor for glioma (P<0.001) (Table 3).Overexpression of LATS1 in glioma U251 cells
To study its biological functions, we introduced the
LATS1 gene into the glioma U251 cell line using
pCDF-GFP lentivirus expression vector. Five (5) stably
transfected cell clones were obtained. Real-time PCR
identified two cell clones (LATS1-2,-4) with the highest
mRNA expression of LATS1 (Figure 2A). Further, LATS1
protein was highly expressed in two cell clones by west-
ern blotting assay with LATS1 antibody,while control
clone cells lacked similar expression (Figure 2B).Table 2 The correlation of LATS1 protein expression with Clin
Clinicopathological
features
Cases (n) Expression Level o
Negative
Age
≥55 47 11
< 55 56 12
Gender
Male 60 13
Female 43 10
WHO grade
I 19 1
II 22 3
III 30 7
IV 32 12
KPS
≥80 53 6
<80 50 14LATS1 inhibits cell proliferation in vitro
To analyze the function of LATS1, we studied the rate
of cell proliferation of LATS1-expressing LATS1-2 and
−4 cells. The growth curves determined by MTT assay
revealed that LATS1 significantly inhibited cell prolifera-
tion of these two lines of cells compared to control clone
cells (Figure 3A). In a colony formation assay LATS1-
overexpressing LATS1-2 and −4 cells formed signifi-
cantly less colonies than control clone cells (P < 0.001
for both cell types) (Figure 3B, Table 4), suggesting the
inhibitory effect of LATS1 on anchorage-dependent
growth of glioma cells.LATS1 suppressed cell migration and invasion
We employed the in vitro migration assay to assess the
migration ability of LATS1-overexpressing U251 cells.
The migration of LATS1-overexpressing LATS1-2 and
−4 cells was significantly slower than that of the control
cells (Figure 4A). Using a boyden chamber coated with
matrigel, we determined changes in cell invasiveness
after 18-h incubation. Compared with the negative con-
trol cells, LATS1-expressing −2 and −4 cells both
showed significantly decreased invasiveness (for both
P < 0.001) (Figure 4B).icopathological features in Glioma
f LATS1 Protein(n) P
Weak Positive Strong
22 9 5
30 11 3 P = 0.752
35 7 5
17 13 3 P = 0.326
6 8 4
11 6 2
19 3 1
16 3 1 P<0.001
28 13 6
24 7 2 P = 0.011
Figure 2 Reexpression of LATS1 in glioma U251 cells. A. Real-
time PCR analysis indicated the highest mRNA expression of LATS1
in two cell clones pLATS1-2 and −4. B. Western blotting assay shows
significantly increased protein expression of LATS1 in pLATS1-2 and
−4 suppressed the expression of cell cycle factor CCNA1 protein
compared to Control-vector cells. β-actin was used as the internal
control.
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To detect the effect of LATS1 on cell cycle, we mea-
sured cell cycle distribution in LATS1-expressing −2
and −4 cells. The G2 phase population was markedly
increased and G1 phase population significantly
decreased in both cell lines compared to the Ctr-
vector cells and U251 cells (P < 0.001). However, in
both two lines the change in S phase population was
not significant (Figure 4C)(Additional file 1: Figure S1)
(Additional file 2: Table S1).Table 3 Summary of univariate and multivariate Cox regressi
Parameter Univariate an
P HR
Age
≥55vs. <55 years 0.069 0.777
Gender
Male vs. female 0.160 0.820
WHO grade
Ivs.II vs.III vs.IV 0.000 1.715
KPS
≥80 vs. < 80 0.000 2.033
LAST1 expression
Strong vs.Positive vs.Weak vs.Negative* 0.000 0.437LATS1 inhibits the expression of CCNA1
In exploring the molecular mechanism of LATS1 tumor-
suppressing function in glioma, we found that restor-
ation of LATS1 expression significantly inhibited
expression of cell cycle factor CCNA1 in glioma U251
cells (Figure 4D). This suggested that LATS1 may be
involved in G2/M cell cycle pathway in glioma.
Discussion
Malignant gliomas occur more frequently than other
types of primary CNS tumors, having a combined inci-
dence of 5–8/100,000 population. Due to its highly inva-
sive nature, median reported survival is less than 1 year
even with aggressive treatment using surgery, radiation,
and chemotherapy [17]. Thus, there is a need for a bet-
ter understanding of the molecular basis of glioma
pathogenesis to improve prognosis prediction and de-
velop targeted, molecular-based therapies.
Accumulating evidence suggests that the LATS (Large
Tumor Suppressor) family of human tumor suppressors
(LATS1 and LATS2) as regulators of cellular homeosta-
sis. Loss of function of either LATS1 or LATS2 leads to
a variety of tumor types including soft tissue sarcomas,
leukemia, as well as breast, prostate, lung and esopha-
geal cancers [18], which suggests they function as tumor
suppressors in tumor pathogenesis. LATS1 gene is
located at chromosome 6q25.1 and its open reading
frame is 3393 bp encoding a 1130-amino acid polypep-
tide with molecular weight of 126.87 kDa. LATS1 ex-
pression is significantly decreased in some tumors
including breast cancer and astrocytoma [13,14], and
this downregulation has been attributed to its promoter
hypermethylation. Negative regulator of oncoprotein
YAP1 in the Hippo signaling pathway plays a pivotal role
in organ size control and tumor suppression by restrict-
ing proliferation and promoting apoptosis. LATS1 phos-
phorylates YAP1 protein and inhibits its translocationon analysis of overall survival duration
alysis Multivariate analysis
95%CI P HR 95%CI
0.593-1.019
0.621-1.082
1.454-2.023 0.000 1.463 1.233-1.735
1.540-2.684 0.000 2.437 1.810-3.283
0.362-0.528 0.000 0.389 0.316-0.478
Figure 3 Overexpression of LATS1 inhibted cell proliferation
in vitro. A. The cell growth of Control-vector cells and pLATS1-2
and −4 cells, were examined by MTT assay over a seven-day period.
*P < 0.05, as compared to control-vector cells. B. The cell growth of
control-vector cells and pLATS1-2 and −4 cells, were examined by
plate colony formation assay. *P < 0.05, as compared to
control-vector cells.
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cell proliferation, cell death, and cell migration [19]. Fur-
thermore, in previous studies LATS1 overexpression
induced cell apoptosis by increasing pro-apoptotic pro-
teins p53 and Bax [11] and suppressed cell proliferation
through p53 upregulation to ensure genomic integrity
[20]. Conversely, knockdown of LATS1 induced cell mi-
gration in HeLa cells [21]. These results together sup-
ported that LATS1 played a suppressive role in tumor
pathogenesis.
In order to assess the role of LATS1 in glioma, we first
performed real-time PCR to measure the expression ofTable 4 Plate clone formation assay among pLATS1-2,
pLATS1-4, and Ctr-vector cells
Cells Number P value
pLATS1-2 45.33 ± 4.16
pLATS1-4 34.67 ± 6.25
Ctr-vector 77.33 ± 7.12 p<0.001LATS1 mRNA transcripts in 17 paired glioma samples
and their adjacent brain tissues. Similar to reports of
other tumor types [13,14], we observed that LATS1 ex-
pression was significantly decreased in 13 glioma tissues
compared to their matched normal tissues. This sug-
gested LATS1 functions as a tumor suppressor in gli-
oma. We validated this downregulation of LATS1
protein by immunohistochemistry. In addition, we found
that LATS1 expression levels were inversely associated
with WHO grade of glioma and KPS. Further, we pre-
sented the evidence that LATS1 protein expression in
glioma was positively correlated with patient’s overall
survival. The patients with lower expression of LATS1
protein had shorter survival time. According to multi-
variate analyses, decreased expression of LATS1 protein
was a significant predictor of poor prognosis for glioma
patients. These results were analogous to Takahashi et
al’s report in the study of breast cancer [13] and strongly
suggested a suppressive role of LATS1 in glioma
tumorigenesis.
Next, we used a gain-of-function approach by introdu-
cing the LATS1 gene into LATS1-negative U251 glioma
cells, to investigate its biological functions. We observed
that overexpression of LATS1 caused significant reduced
in vitro cell growth and G(2)/M arrest. These are con-
sistent with the findings by Yang et al. [11] and Xia et al.
[12] that upregulation of LATS1 suppresses cell growth
and cell cycle progression, which further demonstrates
that the suppressive biological functions of LATS1 are
common to multiple cancers. Additionally, our study
also revealed a novel function of LATS1 in glioma in
suppression of cell migration and invasion. This suggests
LATS1 may be involved in invasion and metastasis of
cancer, a concept which would need to be confirmed by
in vivo animal model. The observations that LATS1 reg-
ulates multiple cellular processes such as cell prolifera-
tion, cell cycle progression, migration, invasion
emphasizes its importance as a therapeutic target for
treating glioma.
In a previous investigation, increased LATS1 expres-
sion inhibited cell proliferation by blocking the G2/M
transition, mainly through inhibition of the kinase activ-
ity of Cdc2/ Cyclin A/B complex [18]. We also observed
that overexpressed LATS1 caused the G2/M phase
blockade in glioma U251 cells. Therefore, we investi-
gated the expression change of CCNA1, a cell cycle fac-
tor in the Cdc2/ Cyclin A/B complex. This gene binds
both CDK2 and CDC2 kinases and thus regulates the
cell cycle transition at G2/M [22-25]. We speculated
CCNA1 might be involved in the cell cycle regulation
pathway of LATS1 in glioma. Consistent with this pre-
sumption, we found that overexpression of LATS1 sig-
nificantly reduced the expression of CCNA1 by western
blot assay in glioma U251 cells. Further investigation is
Figure 4 Increased LATS1 expression inhibited cell migration, invasion and cell cycle progression. (A) Cell migration and (B) invasion
capabilities of pLATS1-2, -4 cells and Control-vector cells, were examined using transwell and boyden chamber assay. Data were presented as
mean± SD for three independent experiments. *P< 0.05, as compared to control-vector cells. C. Cell cycle in pLATS1-2 and −4 cells and
control-vector cells, was determined by FACS Caliber Cytometry. *P< 0.05, as compared to control-vector cells.
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cell cycle pathway in glioma.
Conclusions
Our results indicate that the decreased expression of
LATS1 appears to favor the development of glioma and
might serve a suppressive role in glioma. Further, we ap-
plied a gain-of-function approach and to examine the
biological processes regulated by LATS1 in glioma cells.
We demonstrated the functional importance of LATS1
in suppressing glioma cell growth, migration, invasionand cell cycle transition from G2 to M phase. Finally, we
observed that overexpression of LATS1 could inhibit the
expression of cell cycle factor CCNA1, which might
partly explain the mechanism by which LATS1 in con-
trols cell proliferation.Additional files
Additional file 1: Figure S1. Cell cycle map of pLATS1-2, -4 cells
and Control-vector cells.
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